A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
This PHASE2 trial investigates Mesonephric Gynecologic Cancer and is currently actively recruiting participants. Memorial Sloan Kettering Cancer Center leads this study, which shows 16 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
16 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
May 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- Verastem, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Basking Ridge, United States
- • Commack, United States
- • Harrison, United States
- • Middletown, United States
- • Montvale, United States
- • New York, United States
- • Uniondale, United States